Effect Of Non-genetic Risk Factors On Anti-VEGF Therapy In Wet Age-related Macular Degeneration

Objective: To compare the efficacy of intravitreal injection of conbercept and ranibizumab in the treatment of wet age-related macular degeneration;to investigate the effect of non-genetic risk factors on anti-vascular endothelial growth factor treatment in wet age-related macular degeneration and to provide evidence for individualized treatment.Data and Methods: This retrospective study included 104patients(110eyes)with w AMD treated with ranibizumab or conbercept which comparing the changes of BCVA and CRT after treatment with two different anti-VEGF drugs.Questionnaires about non-genetic factors and medical history were collected.According to whether the best corrected visual acuity obtained 1 line or not,110 eyes were divided into response group and non-response group.Our questionnaire included 10 items,including age,smoking,hypertension,altitude,antioxidant vitamin intake,baseline visual acuity,time of onset,baseline cubic volume,baseline retinal fluid and baseline macular edema.To explore the effects of these 10 factors on the efficacy.Results: There was no statistically significant difference in BCVA and CRT in w AMD patients treated with ranibizumab and conbercept at 1 year.At the main observation site for 6 months,49 eyes(45%)of 110 eyes were classified as unresponsive and 61 eyes(55%)were classified as reactive.Multivariate Logistic regression analysis showed that altitude,hypertension,baseline visual acuity and time of onset were associated with anti-VEGF efficacy in patients with w AMD.The higher the altitude,the hypertension,the worse the baseline vision and the longer the onset time,the worse the curative effect of the patients.there was no significant difference in the times of drug injection between the response group and the non-response group.Conclusion:There was no significant difference between BCVA and CRT in w AMD treated with two different anti-VEGF agents.Predictors of non-genetic factors can help clinicians identify w AMD patients with increased likelihood of nonresponse,thus helping to guide clinical treatment.